Balancing the risk of major bleeding against vascular disease risk in people without atherosclerotic disease.

ABSTRACT:

Background and aims

In the primary prevention setting, low-dose aspirin reduces major vascular events (MVEs) by approximately 11% but increases major bleeding (MB) by 40-50%, implying that net benefit will be most evident when the MVE-to-MB ratio is >4. This study aimed to derive cross-validated risk scores for MB and MVE and use the MVE-to-MB ratio to identify groups who may derive differing net benefits from treatment.

Methods

431 167 UK Biobank participants without known atherosclerotic cardiovascular disease at baseline were followed through record linkage for incident MVEs (myocardial infarction, non-haemorrhagic stroke, transient ischaemic attack, arterial revascularisation or vascular death) and MB (gastrointestinal and intracranial bleeds with hospital admission for

SUBMITTER: Hammami I 

PROVIDER: S-EPMC12322474 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature